Wet AMD

Biosimilar

Diabetic Eye Awareness

Diabetic Macular Edema

Diabetic Retinopathy

Geographic Atrophy

Imaging

Inherited Retinal Diseases

Ophthalmology

Retina Technology

Retinal Surgery

Uveitis

News

All News

Blogs

Media

All Videos

Case-Based Roundtable Series

Expert Interviews

Eyeviews

Insights

Medical World News

Podcasts

Rapid Readouts

Viewpoints

Conference

Conference Coverage

Conference Listing

Publications

Modern Retina Digital Edition

Supplements And Featured Publications

Resources

Between the Lines

CME/CE

EYLEA 8mg for nAMD and DME Treatment

Partners

Subscribe

Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

About

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Modern Retina | Ophthalmology News, Events & Expert Insights

Facebook

LinkedIn

Spotlight

Clinical

1rem

View

Enhancing Outcomes and Reducing Treatment Burden with Advanced Therapies in Neovascular AMD and DME

clinical

Video Series

Outcomes with Raricimab and Choosing Between the New Therapies

Video content above is prompted by the following: 

In clinical trials, faricimab showed noninferior vision outcomes compared to aflibercept 2 mg. What added benefit do you see by targeting Ang-2?

Videos

Panelists discuss how anti-VEGF therapies have dramatically improved visual outcomes in patients with age-related macular degeneration and diabetic macular edema over the past decade. Key challenges persist, including treatment burden, adherence, and identifying optimal dosing regimens for individual patients.

Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

Panelists discuss how aflibercept’s molecular structure contributes to its clinical efficacy as a standard treatment for retinal vascular diseases.

Advantages of the molecular structure of aflibercept

Panelists discuss how treat-and-extend dosing with aflibercept 2 mg allows for individualized treatment intervals while maintaining vision gains. However, optimal extension timing must be carefully determined based on disease activity markers.

Treat-and-Extend Strategy With Aflibercept 

Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar safety profile.

Assessing New Therapies for Retinal Diseases

Panelists discuss how the aflibercept 8 mg higher molecular concentration enables extended durability through increased VEGF binding capacity and longer intraocular drug levels, potentially allowing for less frequent dosing while maintaining efficacy.

Significance of the Higher Molar Dose of Aflibercept 8 mg

Panelists discuss how the phase 3 PULSAR and PHOTON trials demonstrated the efficacy of aflibercept 8 mg through a design comparing 12- and 16-week dosing intervals to the aflibercept 2 mg standard 8-week dosing, with primary end points assessing noninferiority in visual acuity maintenance.

Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg

Panelists discuss how ideal candidates for aflibercept 8 mg include patients with stable disease on current anti-VEGF therapy who seek reduced treatment burden, newly diagnosed patients, and those demonstrating good response to initial loading doses.

Patient Selection for Aflibercept 8 mg

Panelists discuss how faricimab’s bispecific antibody design uniquely targets both VEGF-A and Ang-2 pathways, addressing the complementary role of Ang-2 in vascular destabilization and inflammation in retinal diseases.

Faricimab Molecular Design and Role of Ang-2

Panelists discuss how faricimab’s dual inhibition of Ang-2 provides additional benefits in vascular stability and inflammation reduction beyond VEGF-A suppression alone, potentially leading to improved durability and treatment outcomes in selected patients.

Outcomes with Faricimab and Choosing Between the New Therapies

Panelists discuss how both medications demonstrate favorable safety profiles in clinical trials, with aflibercept 8 mg benefiting from extensive 2-mg safety data, while acknowledging the need to monitor intraocular pressure due to increased injection volume, particularly in at-risk patients.

Safety Profile of New Therapies

Outcomes with Faricimab and Choosing Between the New Therapies

EP: 1.Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

EP: 2.Advantages of the molecular structure of aflibercept

EP: 3.Treat-and-Extend Strategy With Aflibercept

EP: 4.Assessing New Therapies for Retinal Diseases

EP: 5.Significance of the Higher Molar Dose of Aflibercept 8 mg

EP: 6.Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg

EP: 7.Patient Selection for Aflibercept 8 mg

EP: 8.Faricimab Molecular Design and Role of Ang-2

EP: 9.Outcomes with Faricimab and Choosing Between the New Therapies

EP: 10.Safety Profile of New Therapies